標(biāo)題: Titlebook: Acute Myeloid Leukemia in Children; Standard of Care and Daisuke Tomizawa,Edward Anders Kolb,Dirk Reinhardt Book 2024 The Editor(s) (if app [打印本頁] 作者: Interjection 時(shí)間: 2025-3-21 20:09
書目名稱Acute Myeloid Leukemia in Children影響因子(影響力)
書目名稱Acute Myeloid Leukemia in Children影響因子(影響力)學(xué)科排名
書目名稱Acute Myeloid Leukemia in Children網(wǎng)絡(luò)公開度
書目名稱Acute Myeloid Leukemia in Children網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Acute Myeloid Leukemia in Children被引頻次
書目名稱Acute Myeloid Leukemia in Children被引頻次學(xué)科排名
書目名稱Acute Myeloid Leukemia in Children年度引用
書目名稱Acute Myeloid Leukemia in Children年度引用學(xué)科排名
書目名稱Acute Myeloid Leukemia in Children讀者反饋
書目名稱Acute Myeloid Leukemia in Children讀者反饋學(xué)科排名
作者: Cleave 時(shí)間: 2025-3-21 20:58
AML in Distinct Age-Defined Populations of Infants, Adolescents and Young AdultsThis chapter provides an in-depth discussion of de novo acute myeloid leukemia (AML) in children less than 3 years of age, and in adolescents and young adults. The efforts and contributions of each of the major collaborative AML study groups are included and state-of-the art prognostic factors for guiding treatment decisions are reviewed.作者: 惰性氣體 時(shí)間: 2025-3-22 04:02 作者: 輕快來事 時(shí)間: 2025-3-22 07:29 作者: PLIC 時(shí)間: 2025-3-22 11:45 作者: 碌碌之人 時(shí)間: 2025-3-22 15:52 作者: Flounder 時(shí)間: 2025-3-22 20:05
Aufbau und Inhalt des Gutachtensc AML, the most recent classification according to the World Health Organization, and how to diagnose AML. The basis for the initial bone marrow examination is morphological evaluation of bone marrow smear with or without trephine biopsy. Flow cytometry immunophenotyping is used to confirm AML and a作者: brachial-plexus 時(shí)間: 2025-3-22 23:26 作者: Agronomy 時(shí)間: 2025-3-23 03:29
Rechtsgrundlage der Begutachtungcation of chemotherapy, improved identification of patients with higher risk of relapse, advances in hematopoietic stem cell transplantation, and improved supportive care (Zwaan et al., J Clin Oncol 33(27):2949–2962, 2015; Rasche et al., Leukemia 32(10):2167–2177, 2018). The pillars of chemotherapy 作者: 撤退 時(shí)間: 2025-3-23 06:31 作者: 事先無準(zhǔn)備 時(shí)間: 2025-3-23 10:56 作者: STING 時(shí)間: 2025-3-23 17:15 作者: 銼屑 時(shí)間: 2025-3-23 19:23
E. Ludolph,J. R. Rether,K. Weise,F. Schr?ter will review the clinical presentation and diagnostic approaches of children/young adults with myeloproliferative disorders (MPDs). Emphasis in the first section of the chapter will be on MPNs that present in infants and toddlers as well as those that occur in children with constitutional disorders 作者: Feedback 時(shí)間: 2025-3-24 00:41 作者: 小畫像 時(shí)間: 2025-3-24 02:45 作者: 忍耐 時(shí)間: 2025-3-24 06:54 作者: Ischemic-Stroke 時(shí)間: 2025-3-24 14:15 作者: Bridle 時(shí)間: 2025-3-24 15:17 作者: Jingoism 時(shí)間: 2025-3-24 20:57 作者: 容易懂得 時(shí)間: 2025-3-25 00:39 作者: 暴露他抗議 時(shí)間: 2025-3-25 06:29 作者: 共和國 時(shí)間: 2025-3-25 10:44
978-3-031-63368-3The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl作者: 金哥占卜者 時(shí)間: 2025-3-25 13:21 作者: deceive 時(shí)間: 2025-3-25 16:28 作者: 不合 時(shí)間: 2025-3-25 20:26
Grundkurs partielle Differentialgleichungensformation. Future studies prospectively evaluating the utility of tracking molecular evidence of development of MN-pCT in children exposed to cytotoxic agents could lead to early detection and potentially more effective interventions for patients.作者: overwrought 時(shí)間: 2025-3-26 02:30
Gabriele Rosenthal,Nicole Witte anticancer treatment, and adequate supportive care measures. To address these inequalities in childhood cancer outcomes, collaborative efforts should be made to improve the care and survival for all children with cancer.作者: Inferior 時(shí)間: 2025-3-26 05:28
Diagnosis and Classifications of Pediatric AMLlapse for decision regarding allogeneic stem cell transplantation, if targeted treatment can be given, and if there is genetic predisposition. In this chapter, morphological assessment, immunophenotyping, cytogenetics, and molecular genetic techniques including next generation sequencing are described.作者: foliage 時(shí)間: 2025-3-26 09:51 作者: CAND 時(shí)間: 2025-3-26 13:08
Pediatric AML in Resource-Limited Countries anticancer treatment, and adequate supportive care measures. To address these inequalities in childhood cancer outcomes, collaborative efforts should be made to improve the care and survival for all children with cancer.作者: 厚顏無恥 時(shí)間: 2025-3-26 20:24 作者: Accede 時(shí)間: 2025-3-26 23:31 作者: Paraplegia 時(shí)間: 2025-3-27 01:34 作者: Diastole 時(shí)間: 2025-3-27 07:20 作者: 無瑕疵 時(shí)間: 2025-3-27 11:59 作者: CANON 時(shí)間: 2025-3-27 16:10
Germline Predisposition to MDS and AMLhe diagnosis of such syndromes, which involve genes such as ., ., ., ., .. This chapter describes these newly characterized leukemia predisposition syndromes’ genetic, biological, and clinical features.作者: 粗魯性質(zhì) 時(shí)間: 2025-3-27 20:12 作者: CHIDE 時(shí)間: 2025-3-28 01:48
Chromosomal and Genomic Alterations in Pediatric AMLis and prognostication. Clinically significant alterations most often come in the form of fusion oncogenes, chromosome losses, and cancer gene mutations (e.g., single nucleotide variants, insertions/deletions, and internal tandem duplications). Genes that encode transcription factors and signal tran作者: Neutropenia 時(shí)間: 2025-3-28 02:21 作者: NIL 時(shí)間: 2025-3-28 08:53
Diagnosis and Classifications of Pediatric AMLc AML, the most recent classification according to the World Health Organization, and how to diagnose AML. The basis for the initial bone marrow examination is morphological evaluation of bone marrow smear with or without trephine biopsy. Flow cytometry immunophenotyping is used to confirm AML and a作者: 推延 時(shí)間: 2025-3-28 10:43
Measurable Residual Disease Assessment in Pediatric AMLical decision making for patients with acute myeloid leukemia (AML). An appropriate MRD assay should include specificity and stability of the MRD biomarker(s) as well as high sensitivity. Given the heterogeneity of AML, the most appropriate MRD testing approach will be dependent on the biology of th作者: 使害羞 時(shí)間: 2025-3-28 14:37 作者: GUMP 時(shí)間: 2025-3-28 19:42 作者: 類型 時(shí)間: 2025-3-29 01:06
Acute Promyelocytic Leukemia20?years; cure rates above 95% are expected when . retinoic acid (ATRA) is given with arsenic trioxide (ATO) and low-dose anthracyclines. The presenting features of pediatric APL may include severe bleeding and thrombotic complications, which contribute to the high early death rate. The incidence of作者: CHAR 時(shí)間: 2025-3-29 05:01
Myeloid Proliferation Associated with Down Syndrome (ML-DS, TAM) This myeloproliferative disorder is caused by a mutation in the hematopoietic transcription factor GATA1, which is strongly associated with Down syndrome. Despite spontaneous remission without therapy within the first 3?months in most patients, serious complications occur in 5–10% of patients resul作者: 名詞 時(shí)間: 2025-3-29 08:02 作者: 蝕刻 時(shí)間: 2025-3-29 12:35 作者: etidronate 時(shí)間: 2025-3-29 18:26
Advanced MDS in Childrens with 2–19% or bone marrow blasts with 5–19% are classified as advanced MDS. Aging-related somatic variants acquired in the hematopoietic cells are associated with the pathogenesis of adult MDS, whereas pediatric MDS often occurs in the context of germline predispositions. Besides well-known inheri作者: 頭腦冷靜 時(shí)間: 2025-3-29 20:51 作者: 混沌 時(shí)間: 2025-3-30 03:02
Stem Cell Transplantation and Cellular Immunotherapies for Pediatric AMLin patients with high-risk acute myeloid leukemia (AML). Although transplant-related mortality occurs in ~5% of patients, HSCT is still considered the only available curative option for most patients with high-risk AML. Many factors such as the stem cell donor source, conditioning regimen, and time 作者: Basal-Ganglia 時(shí)間: 2025-3-30 07:34
Pediatric AML in Resource-Limited Countriesreas in low- and middle-income countries (LMICs), survival rates are merely 10–40%. Reasons for these differences are the lack of early recognition and referral, the lack of diagnostic and treatment response monitoring capacities, the lack of resources for adequate anticancer treatment, the lack of 作者: GUILT 時(shí)間: 2025-3-30 09:02 作者: 遣返回國 時(shí)間: 2025-3-30 12:21 作者: Chemotherapy 時(shí)間: 2025-3-30 20:14 作者: 不能強(qiáng)迫我 時(shí)間: 2025-3-30 22:00
De Novo AMLle international cooperative groups to conduct clinical and biologic research becomes more critical. This chapter will focus on therapeutic advances in childhood AML in the international cooperative groups, including chemotherapeutic regimens and advances in risk stratification.作者: 完全 時(shí)間: 2025-3-31 02:52 作者: cancer 時(shí)間: 2025-3-31 05:24 作者: Keshan-disease 時(shí)間: 2025-3-31 11:10 作者: heterodox 時(shí)間: 2025-3-31 17:19 作者: Pathogen 時(shí)間: 2025-3-31 18:02
Advanced MDS in Childrenly evaluated to differentiate those features suggestive of germline predisposition and poor prognostic features. Myeloablative allogeneic hematopoietic cell transplantation is generally considered as the only curative option; however, both relapse and transplantation-related mortality are still the
